- Home
- MVO vs ITRM Comparison
MVO vs ITRM Comparison
Compare MVO & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MVO | ITRM |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.3M | 24.3M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | MVO | ITRM |
|---|---|---|
| Price | $1.87 | $0.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 208.5K | ★ 30.9M |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 17.46% | N/A |
| EPS Growth | N/A | ★ 57.43 |
| EPS | ★ 1.46 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $947.65 |
| P/E Ratio | $1.25 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.97 | $0.03 |
| 52 Week High | $6.26 | $1.16 |
Technical Indicators
Market Signals| Indicator | MVO | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 38.57 | 26.10 |
| Support Level | $1.03 | N/A |
| Resistance Level | $2.24 | $0.39 |
| Average True Range (ATR) | 0.16 | 0.02 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 19.95 | 3.34 |
Price Performance
Historical ComparisonAbout MVO MV Oil Trust Units of Beneficial Interests
MV Oil Trust is a statutory trust. The trust was created to acquire and hold the net profits interest for the benefit of the Trust unitholders.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.